MOESM2 of Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study

Cai, Wen; Cai, Biao; Zhou, Juan; Chen, Yonghui; Zhang, Jin; Huang, Yiran; Xue, Wei; Huang, Jiwei

doi:10.6084/m9.figshare.10041764.v1

40880_2019_405_MOESM2_ESM.docx (16.5 kB)

MOESM2 of Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study

journal contribution

posted on 2019-10-24, 13:55 authored by Wen Cai, Biao Cai, Juan Zhou, Yonghui Chen, Jin Zhang, Yiran Huang, Wei Xue, Jiwei Huang

Additional file 2: Table S1. Clinicopathological characteristics and tumor responses of patients with renal cell carcinoma receiving neoadjuvant therapy.

Funding

Shanghai Science and Technology Commission

History

Usage metrics

Keywords

Clinicopathological sunitinib cell carcinoma tumor retrospective neoadjuvant therapy safety efficacy axitinib response MOESM sorafenib characteristic 1.

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

MOESM2 of Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study

Funding

Shanghai Science and Technology Commission

History

Usage metrics

Categories

Keywords

Licence

Exports